πŸ‡ΊπŸ‡Έ FDA
Patent

US 10633434

Anti-C5 antibodies

granted A61KA61K2039/505A61K2039/54

Quick answer

US patent 10633434 (Anti-C5 antibodies) held by REGENERON PHARMACEUTICALS, INC. expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K2039/505, A61K2039/54, A61K39/3955, A61K45/06